An Expandable Informatics Framework for Enhancing Central Cancer Registries with Digital Pathology Specimens, Computational Imaging Tools, and Advanced Mining Capabilities

David J. Foran[1,2], Eric B. Durbin[3,4], Wenjin Chen[1], Evita Sadimin[1,2], Ashish Sharma[5], Imon Banerjee[5], Tahsin Kurc[6], Nan Li[5], Antoinette M. Stroup[7], Gerald Harris[7], Annie Gu[5], Maria Schymura[8], Rajarsi Gupta[6], Erich Bremer[6], Joseph Balsamo[6], Tammy DiPrima[6], Feiqiao Wang[6], Shahira Abousamra[9], Dimitris Samaras[9], Isaac Hands[4], Kevin Ward[10], Joel H. Saltz[6]

[1]Center for Biomedical Informatics, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA, [2]Department of Pathology and Laboratory Medicine, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ, USA, [3]Kentucky Cancer Registry, Markey Cancer Center, University of Kentucky, Lexington, KY, USA, [4]Division of Biomedical Informatics, Department of Internal Medicine, College of Medicine, Lexington, KY, USA, [5]Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA, [6]Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY, USA, [7]New Jersey State Cancer Registry, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA, [8]New York State Cancer Registry, New York State Department of Health, Albany, NY, USA, [9]Department of Computer Science, Stony Brook University, Stony Brook, NY, USA, [10]Georgia State Cancer Registry, Georgia Department of Public Health, Atlanta, GA, USA

Abstract

Background: Population-based state cancer registries are an authoritative source for cancer statistics in the United States. They routinely collect a variety of data, including patient demographics, primary tumor site, stage at diagnosis, first course of treatment, and survival, on every cancer case that is reported across all U.S. states and territories. The goal of our project is to enrich NCI's Surveillance, Epidemiology, and End Results (SEER) registry data with high-quality population-based biospecimen data in the form of digital pathology, machine-learning-based classifications, and quantitative histopathology imaging feature sets (referred to here as *Pathomics features*). **Materials and Methods:** As part of the project, the underlying informatics infrastructure was designed, tested, and implemented through close collaboration with several participating SEER registries to ensure consistency with registry processes, computational scalability, and ability to support creation of population cohorts that span multiple sites. Utilizing computational imaging algorithms and methods to both generate indices and search for matches makes it possible to reduce inter- and intra-observer inconsistencies and to improve the objectivity with which large image repositories are interrogated. **Results:** Our team has created and continues to expand a well-curated repository of high-quality digitized pathology images corresponding to subjects whose data are routinely collected by the collaborating registries. Our team has systematically deployed and tested key, visual analytic methods to facilitate automated creation of population cohorts for epidemiological studies and tools to support visualization of feature clusters and evaluation of whole-slide images. As part of these efforts, we are developing and optimizing advanced search and matching algorithms to facilitate automated, content-based retrieval of digitized specimens based on their underlying image features and staining characteristics. **Conclusion:** To meet the challenges of this project, we established the analytic pipelines, methods, and workflows to

Address for correspondence: Dr. David J. Foran,
Center for Biomedical Informatics, Rutgers Cancer Institute of New Jersey,
195 Little Albany Street, New Brunswick, NJ 08903-2681, USA.
E-mail: foran@cinj.rutgers.edu

Access this article online

Quick Response Code:

Website:
www.jpathinformatics.org

DOI:
10.4103/jpi.jpi_31_21

support the expansion and management of a growing repository of high-quality digitized pathology and information-rich, population cohorts containing objective imaging and clinical attributes to facilitate studies that seek to discriminate among different subtypes of disease, stratify patient populations, and perform comparisons of tumor characteristics within and across patient cohorts. We have also successfully developed a suite of tools based on a deep-learning method to perform quantitative characterizations of tumor regions, assess infiltrating lymphocyte distributions, and generate objective nuclear feature measurements. As part of these efforts, our team has implemented reliable methods that enable investigators to systematically search through large repositories to automatically retrieve digitized pathology specimens and correlated clinical data based on their computational signatures.

INTRODUCTION

The NCI's Surveillance, Epidemiology, and End Results (SEER) program is a coordinated system of 19 cancer registries that is charged with providing timely and accurate data regarding cancer incidence, mortality, treatment, and survival. Pathology datasets currently available in the SEER registries are qualitative in nature, consisting of scoring and staging data captured in normal registry abstracts and pathology reports. Such datasets are generally subject to inter-observer variability, which can result in biases in population-wide studies of cancer incidence, mortality, survival, and prevalence. The main goal of our project is to enrich SEER registry data with high-quality population-based digital biospecimen data in the form of pathology tissue images and detailed computational tissue characterizations and features (also referred to as *Pathomics features*) derived from the images. Examples of Pathomics data include detailed characterizations of cancer and stromal nuclei and quantification and mapping of tumor-infiltrating lymphocytes (TILs) along a supplementary histology classification generated through deep-learning algorithms. These data will augment existing registry data with quantitative features obtained directly from clinically acquired whole slide tissue images and provide detailed and nuanced information on tumor histology.

The scientific premise motivating this work is that the incorporation of quantitative digital pathology into the cancer registries will result in a valuable population-wide dataset that can provide additional insight into the underlying characteristics of cancer. Next Generation Sequencing (NGS) technologies have captured much attention of the clinical community for their capacity to provide insight as to personalized choice in treatment and therapy. A major limitation of NGS technologies is that they obliterate the spatial information associated within and throughout the tumor environment. Histopathology and immunostaining localization techniques preserve this information which is invaluable in making accurate determinations. In fact, it is through the process of histopathology examination that tumor margins/volumes are determined by pathologists prior to the NGS analysis. These parameters are subsequently used to help guide decisions regarding appropriate cut-offs for allele frequencies and drive other components of the overall analysis. Pathomics features extracted from high-resolution pathology images are a quantitative surrogate of what is described in

a pathology report. The important distinction is that these features are reproducible, unlike human observations, which are highly qualitative and subject to a high degree of inter- and intra-observer variability. The importance of increasing reproducibility and reducing inter-observer variability in pathology studies has been previously reported.[1-26] Moreover, many studies have demonstrated that quantitative image characterizations (e.g., nuclear features, patterns of TILs) are promising biomarkers which can be used to predict outcome and treatment response, if available in a large population.[27-39] These biomarkers integrated with clinical and genomics data can provide new opportunities to enhance our understanding of cancer incidence, mortality, survival, along with statistical characterizations of lifetime risk, and to improve prediction and assessment of therapeutic effectiveness.

Our project began as collaboration among investigators within the state cancer registries of New Jersey, Georgia, and Kentucky. The consortium of partnering sites has recently expanded to include the newly established New York Cancer Registry. In this collaborative effort, we are implementing a framework of data curation and analysis workflows, computational imaging tools, and informatics infrastructure to support the creation and management of a well-curated, integrated repository of high-quality digitized pathology images and Pathomics features, for subjects whose data are being collected by the registries. The framework is being developed in close collaboration with SEER registries to ensure that it is scalable and in-line with existing registry processes and can support queries and the creation of population cohorts that span multiple registries.

In our framework, whole slide tissue images in the repository are systematically processed to compute Pathomics data and to establish linkages with registry data. The current set of Pathomics data includes (1) quantification of TILs, (2) segmentation and computational description of cancerous and stromal nuclei, (3) segmentation of tumor regions, (4) characterization of regional Gleason grade for prostate cancer, and (5) identification of non-small cell lung cancer (NSCLC) adenocarcinoma subtypes. This initial set is primarily motivated by an increasing number of scientific studies that investigate TILs and the relationships among TILs, tumors, and nuclear structure of tissue.[40-45] Such investigations can provide important information to advance our understanding of immune response in many cancer types. In the future, additional Pathomics features,

such as the spectral and spatial signatures of staining characteristics exhibited by the digitized specimens, will be incorporated into our framework.

The informatics infrastructure for this project is being built on open-source software and leverages modern software technologies, such as containerization and web-based applications, for a scalable, extensible implementation.[46,47] The infrastructure facilitates visualization of high-resolution whole slide tissue images along with associated Pathomics datasets. User authentication and access controls are implemented to thwart unauthorized access to data. The informatics infrastructure is being expanded to include tools to support content-based image retrieval.

Presently, the repository manages diagnostic whole slide tissue images and analysis results obtained from 772 prostate cases, 1410 NSCLC cases, 70 breast cancer cases, and 48 lymphoma cases from the New Jersey State Cancer Registry and from 198 breast cancer cases from the Georgia State Cancer Registry. The scientific validation of the proposed environment will be undertaken through performance studies led by investigators throughout the four collaborating sites with an overarching focus on breast cancer, colorectal cancer, lymphoma, melanoma, NSCLC, and prostate cancer. We are confident that this repository will enable effective integration of pathology imaging and feature data as an invaluable resource in SEER registries.

In the rest of the paper, we describe the design and implementation of the key components of the framework: the data curation and analysis processes, the initial set of image analysis methods, and the underlying informatics infrastructure for data management and visualization.

MATERIALS AND METHODS

Aggregation, quality control, and linkage of image data

The first component of our framework is the curation of pathology imaging data and linkage with other data from the cancer registries. Image quality control is an essential step, because specimen preparation protocols and tissue scanning procedures may result in imaging artifacts and variations in image quality. We devised and refined a workflow to facilitate the collection and quality control of digitized tissue specimens and linkage of images with correlated data extracted from the cancer registries. Here we describe the workflow deployed at Rutgers and the New Jersey SEER registry; the other sites—Georgia, Kentucky, and New York—are incrementally adopting analogous workflows as approved by their SEER registries and Institutional Review Boards (IRBs).

Figure 1 depicts an instance of the workflow. Specimen retrieval and imaging are coordinated at the Biomedical Informatics Shared Resource (BISR) of Rutgers Cancer Institute of New Jersey (RCINJ). Breast, colorectal, lung, melanoma, and prostate cancer cases suitable for the project exhibiting well-defined tumor type and diagnoses are selected by a pathologist at the RCINJ and Rutgers Robert Wood Johnson Medical School. Cases within approximately a 2-year window are retrieved from onsite storage, whereas others are requested from offsite storage with the help of BioSpecimens Repository Service of RCINJ. After a certified pathologist selects suitable slides according to requirement of each cancer type—e.g., prostate cancer specimens are selected according to the Gleason grade—the specimens are imaged with an Olympus VS120 whole slide scanner with no protected health information appearing in image filename, image metadata, or the images themselves.

Team members from the BISR and NJCR perform cross-specialty review of the data for quality control. A secure, IRB-approved, Oracle-based (Redwood Shores, CA, USA) Clinical Research Data Warehouse is used at Rutgers to facilitate review of imaging and correlated clinical information on an individual patient basis or as part of large cohorts. The data warehouse has been commissioned to house multimodal data (genomics, digital pathology, radiology images). It orchestrates aggregation of information originating from multiple data sources including Electronic Medical Records, Clinical Trial Management Systems, Tumor Registries, Biospecimen Repositories, Radiology and Pathology archives, and Next Generation Sequencing services [Figure 2]. Innovative solutions were implemented in the warehouse to detect and extract unstructured clinical information that was embedded in paper/text documents, including synoptic pathology reports. The Warehouse receives objective oversight by a standing Data Governance Council.[48] An Informatica-based (Redwood City, CA, USA) extraction transformation and load interface (ETL) has been developed to automatically populate the Data Warehouse with data elements originating from the multi-modal data sources. This past year our team worked closely with the Google Healthcare team to successfully create and test an instance of the Data Warehouse on the Google Cloud Platform (GCP). In May 2020, we demonstrated the scalability of the cloud-based ETL, Warehouse, and Data Mart. As part of the project, our team will expand the use of the Warehouse by configuring it to integrate digitized pathology specimens with data originating from all of the collaborating cancer registries.

The images and cases are linked through deidentified ID sequences. The New Jersey State Cancer Registry receives the deidentified ID as well as case information including specific surgery number and date, so that after data retrieval and decoding encrypted fields, the deidentified ID is linked with clinical data associated with the case and, more specifically, with the diagnostic surgery. This ensures that the cancer specimen images are associated with the correct staging of the disease at the time of diagnosis so that it can be used in downstream research. The total corpus of

**Figure 1:** Workflow for assembling linked image/data cohorts

Figure 2: Clinical Research Data Warehouse workflow. The research data warehouse aggregates information from multiple data sources such as electronic health records, tumor registries, and radiology and pathology archives. It facilitates review of imaging data and linked clinical data on a single patient or cohort basis

data comprising the linked data sets encompasses more than 150 data elements, including the de-coded NAACCR data, as shown in Table 1. The de-identified images are analyzed through a set of deep-learning analysis pipelines as described in the subsequent sections.

Extraction of Pathomics features

Development of tissue image analysis methods is a highly active area of research and implementation. A variety of analysis methods for segmentation and classification of objects, regions, and structures (such as nuclei, tumors, glands) in tissue images have been developed. Excellent overviews of existing techniques can be found in several review papers.[49-55] Deep-learning-based analysis approaches have become popular, because deep-learning methods have been shown to outperform traditional image analysis methods in many application domains, including digital pathology. Our current tissue image analysis

library consists of deep-learning methods developed by our group to classify patterns of TILs,[56,57] segment tumor regions, classify tumor subtypes,[58,59] and segment nuclei in whole slide images (WSIs) of hematoxylin and eosin-stained tissue samples.[60,61]

We should note that the analysis functionality is not limited to methods implemented by our group only. We have started with these methods because (1) they are based on state-of-the-art convolutional neural network architectures, such as VGG16,[62] Inception V4,[63] ResNet,[64] and U-Net,[65] (2) they have achieved high accuracy scores, and (3) they have been previously used, refined, and validated in generating large, curated Pathomics datasets. For example, the TIL models were developed in close collaboration with pathologists, who generated a large set of training data, evaluated analysis results, and helped refine the models. The final models were employed to produce and publish a TIL dataset from 5202 WSIs from 13 cancer types.[56,57] The nucleus segmentation model was developed in a similar approach with one difference. In addition to manually annotated segmentations, a synthetic data generation method, based on generative adversarial networks,[66] was used to significantly increase the diversity and size of training data.[60] The model trained with the combined manual and synthetic training data was used to generate a quality-controlled dataset of 5 billion segmented nuclei in 5060 WSIs from 10 cancer types[61] in the Cancer Genome Atlas (TCGA) repository. We plan to expand the suite of analysis methods and incorporate state-of-the-art methods developed by other groups over time. Indeed, at the time of writing this manuscript, we are in the process of integrating and validating Hover-Net[67] in the framework for segmentation and classification of nuclei.

The current suite of TIL analysis models can resolve TIL distributions in a WSI at the level of 50×50 μm^2 patches. The characteristics of tumor regions and the relationship between tumor regions and lymphocyte cells can be used to determine cancer stage and evaluate response to treatment. Our current models can segment tumor regions in lung, prostate, pancreatic, and breast cancer types and can classify tumor and non-tumor regions at the level of 88×88 μm^2 patches. The model for prostate cancer can segment and label a tumor subregion with one of the three Gleason scores: Benign, Grade 3, and Grade 4+5. The lung tumor segmentation model is able to segment and label a tumor subregion with one of the six tumor subtypes: acinar, benign, lepidic, micropapillary, mucinous, and solid. Nucleus segmentation is one of the core digital pathology analysis steps. The shape and texture properties and spatial distributions of nuclei in tissue specimens are used in cancer diagnosis and staging. Our nucleus segmentation model can detect nuclei and delineate their boundaries in WSIs. After a WSI has been processed by the segmentation model, we compute a set of shape, intensity, and texture features. We use the PyRadiomics library[68] to compute the patch-level features.

Management, visualization, and review of Pathomics features

Our data analysis workflow implements an iterative *train-predict-review-refine* process to curate robust Pathomics features. This process is based on our earlier works in curating large Pathomics datasets[57,59,61] and is carried out as part of the training and prediction phases of the deep-learning analysis pipelines. We developed a set of tools to enable the iterative process and to provide support for the management, indexing, and interactive viewing of WSIs and analysis results. The tools are implemented as a set of web-based applications and services in the PRISM and QuIP software platforms.[46,47] Using these tools, pathologists can inspect the output of a tumor or TIL analysis pipeline as full-resolution heatmap overlays on WSIs. A heatmap is a spatial representation of prediction probabilities assigned to individual image patches by the deep-learning model; the probability value indicates if a

Table 1: Representative categories and linked data elements

Source	Category	Representative elements
Cancer Registry	Demographics	age_at_dx, sex, marital_status_at_dx, race, nhia, napiia, county_at_dx, etc
	Vital information	vital_status, date_of_death, primary_cause
	Tumor information	Primary_site, laterality, grade, diagnosis_confirmation
	Tumor extension and metastasis	cs_extension, cs_tumor_size, cs_lymph_nodes, cs_mets_at_dx
	Pathology info and tumor staging	histology_icdo3, behavior_icdo3, clinical and pathology staging in AJCC 6, 7, 8 and SEER staging
	Site-specific data	cs_site_specific factors
	Tumor treatments	Surgical, radiation, hormone, BRM, and other cancer treatment information
Imaging	Pathology images	Digitized representative diagnostic slides in Olympus (.vsi) and Philips (.svs?) whole slide image formats, including image metadata such as imaging device, optical settings and configuration, specimen staining, etc.
	Computational imaging signatures	Tumor-infiltrating lymphocytes; tumor pattern segmentation; tumor and stromal nuclei segmentation; spatial and spectral signatures

patch is class-positive (e.g., TIL-positive, tumor-positive). Figure 3 shows example heatmaps generated from the TIL (upper figure) and tumor (lower figure) analysis pipelines. Nuclear segmentation results can be viewed as polygons, which represent the boundaries of segmented nuclei as overlays on the images in QuIP [Figure 4].

Figure 5 shows how the iterative process is executed with QuIP. For example, after a set of WSIs are processed by the TIL and tumor segmentation models, the source WSIs and the heatmaps are loaded to QuIP for management and visualization. The heatmaps and WSIs are also transformed into feature maps. Feature maps are lower resolution representations of the heatmaps and WSIs in a four-panel image. Figure 6 illustrates an example feature map which combines TIL results from a VGG16 model and tumor segmentation results from a ResNet model. The upper left corner of the image is the low-resolution tissue image, the upper right corner is the tumor segmentation map, the lower left corner represents the TIL map, and the lower right corner is the combined and thresholded TIL and tumor maps. Feature maps allow a pathologist to review results more efficiently than examining full-resolution images and maps. If the pathologist sees potential problems with the results during this review, they use the web applications in QuIP to visualize the WSIs and heatmaps at higher resolutions. If the review necessitates refinements to the model, additional training data are generated and added to the training dataset. They can annotate regions in an image using web-based visualization and annotation tools. Patches extracted from these annotations are reviewed and labeled to create additional training data. The model is refined by re-training the method with the updated training dataset.

RESULTS

The current implementation of the framework—the curation and analysis workflows, analysis methods, and informatics infrastructure—has been successfully deployed. The workflows and analytic methods have received IRB approval at all collaborating institutions. The framework has been employed to create a repository of diagnostic images from 772 prostate cases, 1410 NSCLC cases, 70 breast cancer cases, and 48 lymphoma cases from the New Jersey State Cancer Registry and from 198 breast cancer cases from the Georgia State Cancer Registry. The repository also contains results from TIL and tumor segmentation for each image and more than 2.5 billion segmented nuclei from all of the images. For each image, there are two TIL analysis results (one generated from the VGG16 network and the other from the Inception V4 network). The images and Pathomics data are managed by an instance of QuIP running at Stony Brook for interactive visualization of images and Pathomics features. All of the results and images are also stored in Box folders to facilitate bulk data downloads.


Figure 3: TIL and tumor analysis results displayed as a heatmap on the whole slide tissue image. TIL analysis results on the left and the tumor segmentation results on the right. The red color indicates a higher probability of a patch being TIL-positive (or tumor-positive) and the blue color indicates a lower probability

DISCUSSION AND CONCLUSIONS

Evaluation of cancer control interventions in prevention, screening, and treatment and their effects on population trends in incidence and mortality hinge on accurate, reproducible, and nuanced pathology characterizations. Diagnostic and treatment guidelines also specify detailed measurements of TILs, nuclear grade; i.e., evaluation of the size and shape of the nucleus in the tumor cells, mitoses, and IHC staining, which are currently not included in cancer registry data abstraction. Presently, the SEER Pathology workflow, depicted in Figure 7, begins with normal registry abstracts and electronic pathology (e-Path) reports securely transmitted to the SEER registries. Although scoring and staging data are captured and made available through the registries, there have been numerous studies that showed a high level of inter-observer variability among the diagnostic classifications rendered by pathologists, which can potentially give rise to biases when conducting population-wide studies. As the diagnosis of cancer and its immune response to therapy is made through tissue studies, the integration of pathology

Figure 4: Segmented nuclei overlaid as polygons shown in blue on the WSI. Each polygon represents the boundary of a segmented nucleus


Figure 5: The iterative workflow starts with a set of patches which are extracted from whole slide tissue images and labeled for initial model training. Predictions from the trained model are reviewed as feature maps and heatmaps. The heatmaps are annotated to generate additional labeled patches which are added to the training dataset. The deep learning network is retrained with the updated training dataset to refine the model

imaging in SEER registries is critical to precisely classify tumors and predict tumor response to therapies.

Whole slide tissue scanning technologies have advanced significantly over the past 20 years.[69] They are capable of imaging tissue specimens at high resolution in several minutes, and with advanced auto-focussing mechanisms and automated slide trays, they can process batches of tissue samples with little-to-no manual intervention. Several studies have evaluated the utility of imaged tissue data in pathology workflows.[70-75] The Food and Drug Administration has approved a number of digital pathology systems for diagnostic use.[76] We expect that digital pathology will be employed increasingly as part of routine pathology workflows at hospitals and medical research centers. As institutions adopt digital WSIs into their pathology workflows, we can envision that the images and molecular reports will also be securely transmitted to the SEER registries. Within the SEER registry, images will be automatically processed by the suite of feature extraction pipelines appropriate for the type of cancer. The SEER database will be enhanced with quantitative features and the accompanying pipeline distribution version. SEER*DMS will be used to link and integrate cancer abstracts, e-Path reports, WSIs, and Pathomics feature sets from all reporting facilities. De-identified images and annotations will then be extracted for data mining and

Figure 6: A feature map representation of TIL and tumor analysis results generated from a WSI in the Cancer Genome Atlas repository. The low-resolution version of the input WSI is displayed in the upper left corner. The upper right corner is the tumor segmentation map. The TIL map is displayed in the lower left corner. The lower right corner is the combined and thresholded TIL and tumor maps

research use. Our work on building a repository of curated WSIs and Pathomics features is an important step toward realizing this capability. Availability of tissue images and Pathomics datasets will also provide an invaluable resource for medical education and Pathology training as well as to facilitate multi-disciplinary approaches, improved quality control, and more efficient remote and collaborative access to tissue information.[77,78]

The first phase of our project focussed on the collection of cases and correlated pathology specimens from the archives of New Jersey State Cancer Registries and Rutgers Cancer Institute of New Jersey and on targeted prostate and NSCLC cases. To date, we have established a repository of (1) high-quality digitized pathology images for subjects whose data are already being routinely collected by the collaborating registries and (2) Pathomics features consisting of patterns of TILs, tumor region segmentations and classifications, and segmented nuclei. We have completed the initial linkages with registry data, thus enabling the creation of information-rich, population cohorts containing objective imaging and clinical attributes that can be mined. As part of the second phase of the effort, we have increased the number of contributing state registries to include Georgia, Kentucky, and New York and we have simultaneously expanded the scope of cancers under study by including melanoma, breast, and colorectal cancers. We will also build upon our team's previous research efforts to

design, develop, and optimize algorithms and methods that can quickly and reliably search through a growing reference library of cases to automatically identify and retrieve previously analyzed lesions which exhibit the most similar characteristics to a given query case for clinical decision support[20-22,25,79-86] and to conduct more granular comparisons of tumors within and across patient populations. One of the potential advantages of this approach over purely alphanumeric search strategies is that it will enable investigators to systematically interrogate the data while visualizing the most relevant digitized pathology specimens.[32,33]

As part of the next phase of our project, we plan to investigate the automated nature of the full range of algorithms and methods for their capacity to enable clinicians and investigators to quickly and reliably answer questions such as: (a) What level of morphological variations are detected among a given set of tumors or specimens? (b) What changes in computational biomarker signatures occur at onset and key stages of disease progression? (c) What is the likely prognosis for a given patient population?

Software availability

The QuIP software and analysis methods are available as open-source codes for use by other research groups. The QuIP software platform can be downloaded and built from https://github.com/SBU-BMI/quip_distro.

Figure 7: Pathology image workflow. WSIs are de-identified and analyzed by deep-learning analysis pipelines deployed in containers. Image data are linked to the SEER Registry database to enhance it with quantitative imaging features (such as TIL distributions and tumor segmentations) extracted by deep-learning models. De-identified images and imaging features can then be used for data mining and research purposes

The codes for the analysis methods can be accessed from links at https://github.com/SBU-BMI/histopathology_analysis.

Conflicts of interest

There are no conflicts of interest.

References

1. Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: General pathologist. Hum Pathol 2001;32:81-8.

2. Berney DM, Algaba F, Camparo P, Compérat E, Griffiths D, Kristiansen G, *et al*. The reasons behind variation in Gleason grading of prostatic biopsies: Areas of agreement and misconception among 266 European pathologists. Histopathology 2014;64:405-11.

3. Bueno-de-Mesquita JM, Nuyten DS, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol 2010;21: 40-7.

4. Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, *et al*. Validation of interobserver agreement in lung cancer assessment: Hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: The 2004 World Health Organization classification and therapeutically relevant subsets. Arch Pathol Lab Med 2013;137:32-40.

5. Matasar MJ, Shi W, Silberstien J, Lin O, Busam KJ, Teruya-Feldstein J, *et al*. Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification. Ann Oncol 2012;23:159-66.

6. Muenzel D, Engels HP, Bruegel M, Kehl V, Rummeny EJ, Metz S. Intra- and inter-observer variability in measurement of target lesions: Implication on response evaluation according to RECIST 1.1. Radiol Oncol 2012;46:8-18.

7. Nakazato Y, Maeshima AM, Ishikawa Y, Yatabe Y, Fukuoka J, Yokose T, *et al*. Interobserver agreement in the nuclear grading of primary pulmonary adenocarcinoma. J Thorac Oncol 2013;8:736-43.

8. Netto GJ, Eisenberger M, Epstein JI; TAX 3501 Trial Investigators. Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologists: Findings of TAX 3501 multinational clinical trial. Urology 2011;77:1155-60.

9. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, *et al*. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012;7:42.

10. Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R. Lung cancer heterogeneity: A blinded and randomized study of 100 consecutive cases. Hum Pathol 1985;16:569-79.

11. Sørensen JB, Hirsch FR, Gazdar A, Olsen JE. Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma. Cancer 1993;71:2971-6.

12. Warth A, Stenzinger A, von Brünneck AC, Goeppert B, Cortis J, Petersen I, *et al*. Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas. Eur Respir J 2012;40:1221-7.

13. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, *et al*. Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes. Blood 2008;111:60-70.

14. Yoon SH, Kim KW, Goo JM, Kim DW, Hahn S. Observer variability in RECIST-based tumour burden measurements: A meta-analysis. Eur J Cancer 2016;53:5-15.

15. Bennett JM. The FAB/MIC/WHO proposals for the classification of the chronic lymphoid leukemias. Rev Clin Exp Hematol 2002;6:330-4.

16. Head DR, Savage RA, Cerezo L, Craven CM, Bickers JN, Hartsock R, *et al*. Reproducibility of the French-American-British classification of acute leukemia: The Southwest Oncology Group Experience. Am J Hematol 1985;18:47-57.

17. Baumann I, Nenninger R, Harms H, Zwierzina H, Wilms K, Feller AC, *et al*. Image analysis detects lineage-specific morphologic markers in leukemic blast cells. Am J Clin Pathol 1996;105:23-30.

18. Gabril MY, Yousef GM. Informatics for practicing anatomical pathologists: Marking a new era in pathology practice. Mod Pathol 2010;23:349-58.

19. Wedman P, Aladhami A, Beste M, Edwards MK, Chumanevich A, Fuseler JW, *et al*. A new image analysis method based on morphometric and fractal parameters for rapid evaluation of *in situ* mammalian mast cell status. Microsc Microanal 2015;21:1573-81.

20. Foran DJ, Comaniciu D, Meer P, Goodell LA. Computer-assisted discrimination among malignant lymphomas and leukemia using immunophenotyping, intelligent image repositories, and telemicroscopy. IEEE Trans Inf Technol Biomed 2000;4:265-73.

21. Yang L, Tuzel O, Chen W, Meer P, Salaru G, Goodell LA, *et al*. Pathminer: A web-based tool for computer-assisted diagnostics in pathology. IEEE Trans Inf Technol Biomed 2009;13:291-9.

22. Foran DJ, Yang L, Chen W, Hu J, Goodell LA, Reiss M, *et al*. Imageminer: A software system for comparative analysis of tissue microarrays using content-based image retrieval, high-performance computing, and grid technology. J Am Med Inform Assoc 2011;18:403-15.

23. Kurc T, Qi X, Wang D, Wang F, Teodoro G, Cooper L, *et al*. Scalable analysis of big pathology image data cohorts using efficient methods and high-performance computing strategies. BMC Bioinform 2015;16:399.

24. Ren J, Karagoz K, Gatza ML, Singer EA, Sadimin E, Foran DJ, *et al*. Recurrence analysis on prostate cancer patients with Gleason score 7 using integrated histopathology whole-slide images and genomic data through deep neural networks. J Med Imaging (Bellingham) 2018;5:047501.

25. Chen W, Meer P, Georgescu B, He W, Goodell LA, Foran DJ. Image mining for investigative pathology using optimized feature extraction and data fusion. Comput Methods Programs Biomed 2005;79:59-72.

26. Girolami I, Gambaro G, Ghimenton C, Beccari S, Caliò A, Brunelli M, *et al*. Pre-implantation kidney biopsy: Value of the expertise in determining histological score and comparison with the whole organ on a series of discarded kidneys. J Nephrol 2020;33:167-76.

27. Yu KH, Zhang C, Berry GJ, Altman RB, Ré C, Rubin DL, *et al*. Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat Commun 2016;7:12474.

28. Romo-Bucheli D, Janowczyk A, Gilmore H, Romero E, Madabhushi A. Automated tubule nuclei quantification and correlation with oncotype DX risk categories in ER+ breast cancer whole slide images. Sci Rep 2016;6:32706.

29. Leo P, Lee G, Shih NN, Elliott R, Feldman MD, Madabhushi A. Evaluating stability of histomorphometric features across scanner and staining variations: Prostate cancer diagnosis from whole slide images. J Med Imaging (Bellingham) 2016;3:047502.

30. Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, Rong Y, *et al*. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 2012;180:2108-19.

31. Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, *et al*. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncol Rep 2010;23:1213-20.

32. Beck AH, Sangoi AR, Leung S, Marinelli RJ, Nielsen TO, van de Vijver MJ, *et al*. Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med 2011;3:108ra113.

33. Jögi A, Vaapil M, Johansson M, Påhlman S. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. Ups J Med Sci 2012;117:217-24.

34. Ojansivu V, Linder N, Rahtu E, Pietikäinen M, Lundin M, Joensuu H, *et al*. Automated classification of breast cancer morphology in histopathological images. Diagn Pathol 2013;8:1-4.

35. Cheng J, Mo X, Wang X, Parwani A, Feng Q, Huang K. Identification of topological features in renal tumor microenvironment associated with patient survival. Bioinformatics 2018;34:1024-30.

36. Chennubhotla C, Clarke LP, Fedorov A, Foran D, Harris G, Helton E, *et al*. An assessment of imaging informatics for precision medicine in cancer. Yearb Med Inform 2017;26:110-9.

37. Colen R, Foster I, Gatenby R, Giger ME, Gillies R, Gutman D, *et al*. NCI workshop report: Clinical and computational requirements for correlating imaging phenotypes with genomics signatures. Transl Oncol 2014;7:556-69.

38. Luo X, Zang X, Yang L, Huang J, Liang F, Rodriguez-Canales J, *et al*. Comprehensive computational pathological image analysis predicts lung cancer prognosis. J Thorac Oncol 2017;12:501-9.

39. Wang C, Pécot T, Zynger DL, Machiraju R, Shapiro CL, Huang K. Identifying survival associated morphological features of triple negative breast cancer using multiple datasets. J Am Med Inform Assoc 2013;20:680-7.

40. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, *et al*.; Cancer Genome Atlas Research Network. The immune landscape of cancer. Immunity 2019;51:411-2.

41. Tille JC, Vieira AF, Saint-Martin C, Djerroudi L, Furhmann L, Bidard FC, *et al*. Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Mod Pathol 2020;33:2198-207.

42. Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, *et al*.; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of tumor infiltrating lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer 2020;6:16.

43. Koh J, Kim S, Kim MY, Go H, Jeon YK, Chung DH. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma. Oncotarget 2017;8:13762-9.

44. Eriksen AC, Sørensen FB, Lindebjerg J, Hager H, dePont Christensen R, Kjær-Frifeldt S, *et al*. The prognostic value of tumor-infiltrating lymphocytes in stage II colon cancer. A nationwide population-based study. Transl Oncol 2018;11:979-87.

45. Zito Marino F, Ascierto PA, Rossi G, Staibano S, Montella M, Russo D, *et al*. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? Exp Opin Biol Ther 2017;17:735-46.

46. Saltz J, Sharma A, Iyer G, Bremer E, Wang F, Jasniewski A, *et al*. A containerized software system for generation, management, and exploration of features from whole slide tissue images. Cancer Res 2017;77:e79-82.

47. Sharma A, Tarbox L, Kurc T, Bona J, Smith K, Kathiravelu P, *et al*. PRISM: A platform for imaging in precision medicine. JCO Clin Cancer Inform 2020;4:491-9.

48. Foran DJ, Chen W, Chu H, Sadimin E, Loh D, Riedlinger G, *et al*. Roadmap to a comprehensive clinical data warehouse for precision medicine applications in oncology. Cancer Inform 2017;16:1176935117694349.

49. Madabhushi A, Lee G. Image analysis and machine learning in digital pathology: Challenges and opportunities. Med Image Anal 2016;33:170-5.

50. Wang S, Yang DM, Rong R, Zhan X, Xiao G. Pathology image analysis using segmentation deep learning algorithms. Am J Pathol 2019;189:1686-98.

51. Bozorgtabar B, Mahapatra D, Zlobec I, Rau TT, Thiran JP. Editorial: Computational pathology. Front Med (Lausanne) 2020;7:245.

52. Deng S, Zhang X, Yan W, Chang EI, Fan Y, Lai M, *et al*. Deep learning in digital pathology image analysis: A survey. Front Med 2020;14:470-87.

53. Niazi MKK, Parwani AV, Gurcan MN. Digital pathology and artificial intelligence. Lancet Oncol 2019;20:e253-61.

54. Gurcan MN, Boucheron LE, Can A, Madabhushi A, Rajpoot NM, Yener B. Histopathological image analysis: A review. IEEE Rev Biomed Eng 2009;2:147-71.

55. Panayides AS, Amini A, Filipovic ND, Sharma A, Tsaftaris SA, Young A, *et al*. AI in medical imaging informatics: Current challenges and future directions. IEEE J Biomed Health Inform 2020;24:1837-57.

56. Abousamra S, Hou L, Gupta R, Chen C, Samaras D, Kurc T, *et al*. Learning from thresholds: Fully automated classification of tumor infiltrating lymphocytes for multiple cancer types. arXiv [eess.IV] 2019. [updated 2019 Jul 9; cited 2021 Oct 19]. Available from: http://arxiv.org/abs/1907.03960.

57. Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, *et al*.; Cancer Genome Atlas Research Network. Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. Cell Rep 2018;23:181-93.e7.

58. Le H, Samaras D, Kurc T, Gupta R, Shroyer K, Saltz J. Pancreatic cancer detection in whole slide images using noisy label annotations. In: Medical Image Computing and Computer Assisted Intervention (MICCAI), October 13-17, 2019, Shenzhen, China. New York: Springer; 2019. p. 541-9.

59. Le H, Gupta R, Hou L, Abousamra S, Fassler D, Torre-Healy L, *et al*. Utilizing automated breast cancer detection to identify spatial distributions of tumor-infiltrating lymphocytes in invasive breast cancer. Am J Pathol 2020;190:1491-504.

60. Hou L, Agarwal A, Samaras D, Kurc TM, Gupta RR, Saltz JH. Robust histopathology image analysis: To label or to synthesize? Proc IEEE Comput Soc Conf Comput Vis Pattern Recognit 2019;2019:8533-42.

61. Hou L, Gupta R, Van Arnam JS, Zhang Y, Sivalenka K, Samaras D, *et al*. Dataset of segmented nuclei in hematoxylin and eosin stained histopathology images of ten cancer types. Sci Data 2020;7:185.

62. Simonyan K, Zisserman A. Very deep convolutional networks for large-scale image recognition. arXiv [cs.CV] 2014. [updated 2015 Apr 10; cited 2021 Oct 19]. Available from: http://arxiv.org/abs/1409.1556.

63. Szegedy C, Ioffe S, Vanhoucke V, Alemi A. Inception-v4, Inception-ResNet and the impact of residual connections on learning. AAAI 2017;31. Available from: https://ojs.aaai.org/index.php/AAAI/article/view/11231.

64. He K, Zhang X, Ren S, Sun J. Deep residual learning for image recognition. In: Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition, June 27-30, 2016, Las Vegas, NV. Piscataway, NJ: IEEE; 2016. p. 770-8.

65. Falk T, Mai D, Bensch R, Çiçek Ö, Abdulkadir A, Marrakchi Y, *et al*. U-net: Deep learning for cell counting, detection, and morphometry. Nat Methods 2019;16:67-70.

66. Goodfellow IJ, Pouget-Abadie J, Mirza M, Xu B, Warde-Farley D, Ozair S, *et al*. Generative adversarial networks. arXiv [stat.ML] 2014. [updated 2014 Jun 10; cited 2021 Oct 19]. Available from: http://arxiv.org/abs/1406.2661.

67. Graham S, Vu QD, Raza SEA, Azam A, Tsang YW, Kwak JT, *et al*. HoVer-Net: Simultaneous segmentation and classification of nuclei in multi-tissue histology images. Med Image Anal 2019;58:101563.

68. van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, *et al*. Computational radiomics system to decode the radiographic phenotype. Cancer Res 2017;77:e104-7.

69. Pantanowitz L, Sharma A, Carter AB, Kurc T, Sussman A, Saltz J. Twenty years of digital pathology: An overview of the road travelled, what is on the horizon, and the emergence of vendor-neutral archives. J Pathol Inform 2018;9:40.

70. Brunelli M, Beccari S, Colombari R, Gobbo S, Giobelli L, Pellegrini A, *et al*. iPathology cockpit diagnostic station: Validation according to College of American Pathologists Pathology and Laboratory Quality Center recommendation at the hospital trust and University of Verona. Diagn Pathol 2014;9(Suppl. 1):S12.

71. Griffin J, Treanor D. Digital pathology in clinical use: Where are we now and what is holding us back? Histopathology 2017;70:134-45.

72. Zarella MD, Bowman D, Aeffner F, Farahani N, Xthona A, Absar SF, *et al*. A practical guide to whole slide imaging: A white paper from the digital pathology association. Arch Pathol Lab Med 2019;143:222-34.

73. Aeffner F, Zarella MD, Buchbinder N, Bui MM, Goodman MR, Hartman DJ, *et al*. Introduction to digital image analysis in whole-slide imaging: A white paper from the Digital Pathology Association. J Pathol Inform 2019;10:9.

74. Lee JJ, Jedrych J, Pantanowitz L, Ho J. Validation of digital pathology for primary histopathological diagnosis of routine, inflammatory dermatopathology cases. Am J Dermatopathol 2018;40:17-23.

75. Pantanowitz L, Michelow P, Hazelhurst S, Kalra S, Choi C, Shah S, *et al*. A digital pathology solution to resolve the tissue floater conundrum. Arch Pathol Lab Med 2021;145:359-64.

76. Evans AJ, Bauer TW, Bui MM, Cornish TC, Duncan H, Glassy EF, *et al*. US Food and Drug Administration approval of whole slide imaging for primary diagnosis: A key milestone is reached and new questions are raised. Arch Pathol Lab Med 2018;142:1383-7.

77. Eccher A, Neil D, Ciangherotti A, Cima L, Boschiero L, Martignoni G, *et al*. Digital reporting of whole-slide images is safe and suitable for assessing organ quality in preimplantation renal biopsies. Hum Pathol 2016;47:115-20.

78. Cima L, Brunelli M, Parwani A, Girolami I, Ciangherotti A, Riva G, *et al*. Validation of remote digital frozen sections for cancer and transplant intraoperative services. J Pathol Inform 2018;9:34.

79. Tuzel O, Yang L, Meer P, Foran DJ. Classification of hematologic malignancies using texton signatures. Pattern Anal Appl 2007;10:277-90.

80. Cukierski WJ, Nandy K, Gudla P, Meaburn KJ, Misteli T, Foran DJ, *et al*. Ranked retrieval of segmented nuclei for objective assessment of cancer gene repositioning. BMC Bioinform 2012;13:232.

81. Qi X, Wang D, Rodero I, Diaz-Montes J, Gensure RH, Xing F, *et al*. Content-based histopathology image retrieval using CometCloud. BMC Bioinform 2014;15:287.

82. Yang L, Qi X, Xing F, Kurc T, Saltz J, Foran DJ. Parallel content-based sub-image retrieval using hierarchical searching. Bioinformatics 2014;30:996-1002.

83. Chen W, Schmidt C, Parashar M, Reiss M, Foran DJ. Decentralized data sharing of tissue microarrays for investigative research in oncology. Cancer Inform 2007;2:373-88.

84. Yang L, Chen W, Meer P, Salaru G, Feldman MD, Foran DJ. High throughput analysis of breast cancer specimens on the grid. Med Image Comput Comput Assist Interv 2007;10:617-25.

85. Qi X, Kim H, Xing F, Parashar M, Foran DJ, Yang L. The analysis of image feature robustness using CometCloud. J Pathol Inform 2012;3:33.

86. Chen Y, McGee J, Chen X, Doman TN, Gong X, Zhang Y, *et al*. Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS One 2014;9:e98293.